123 results
Page 4 of 7
8-K
EX-99.1
o7g5jcuzm4e59b3yxw0f
15 Jul 20
Other Events
7:32am
8-K
EX-99.1
saa49qk
4 Jun 20
David Meline Joins Moderna as Chief Financial Officer
4:06pm
8-K
EX-99.1
9gxs9nztkux07zb
20 May 20
Moderna Announces Pricing of Public Offering of Shares of Common Stock
5:15pm
424B5
go805y
20 May 20
Prospectus supplement for primary offering
5:11pm
S-3ASR
7s5wmtp vus5kvis
18 May 20
Automatic shelf registration
4:13pm
8-K
EX-99.1
b5sz x6sl0
18 May 20
Moderna Announces Positive Interim Phase 1 Data for its mRNA Vaccine (mRNA-1273) Against Novel Coronavirus
7:37am
8-K
EX-99.1
j7jmo1 yn6o
7 May 20
Moderna Reports First Quarter 2020 Financial Results and Provides Business Updates
7:12am
8-K
EX-99.1
ozn3lw34
17 Apr 20
Moderna Announces Award from U.S. Government Agency BARDA for up to $483 Million to
12:00am
8-K
pshr8jkbszu143 6h97j
17 Apr 20
Moderna Announces Award from U.S. Government Agency BARDA for up to $483 Million to
12:00am
8-K
EX-99.1
of3k1
14 Apr 20
Moderna Highlights Opportunity of mRNA Vaccines at its First Vaccines Day
7:13am
DEFA14A
9kio8aiw u8
10 Apr 20
Additional proxy soliciting materials
4:43pm
8-K
5e30tdgskd9i6 rt2yh
31 Mar 20
Regulation FD Disclosure
6:08am
8-K
EX-99.1
tvf ljwuzz0w8fypahtz
30 Mar 20
Moderna Provides Update on the Impact ofCOVID-19 on Business Operations and Clinical Program
7:00am
8-K
zdcug
23 Mar 20
Regulation FD Disclosure
8:32am
8-K
EX-99.2
o8o34 j67xomcwp
16 Mar 20
Regulation FD Disclosure
4:08pm
8-K
EX-99.1
8hunffg i66s9
26 Feb 20
Moderna Reports 2019 Fourth Quarter and Full Year Financial Results and Highlights Advancements in Core Modalities
7:13am
8-K
EX-99.1
fdu0 2hpt
12 Feb 20
Moderna Announces Pricing of Public Offering of Shares of Common Stock
4:55pm